GCGR and metabolic dysfunction-associated steatohepatitis: Cotadutide, a dual GLP-1 and glucagon receptor (GCGR) agonist, has been reported to improve inflammation and fibrosis in NASH animals and this effect was stronger than that of liraglutide.